Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

BACKGROUND: Docetaxel, pemetrexed, erlotinib, and gefitinib are recommended as second-line treatment for advanced non-small cell lung cancer (NSCLC) with wild-type or unknown status for epidermal growth factor receptor (EGFR). However, the number of published randomized clinical trials (RCTs) on thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Créquit, Perrine, Chaimani, Anna, Yavchitz, Amélie, Attiche, Nassima, Cadranel, Jacques, Trinquart, Ludovic, Ravaud, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662096/
https://www.ncbi.nlm.nih.gov/pubmed/29082855
http://dx.doi.org/10.1186/s12916-017-0954-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662096/
https://www.ncbi.nlm.nih.gov/pubmed/29082855
http://dx.doi.org/10.1186/s12916-017-0954-x

Ejemplares similares